Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pulmonary Embolism | 16 | 2021 | 4775 | 1.29 | Why? |
| Ventricular Dysfunction, Right | 2 | 2019 | 639 | 0.52 | Why? |
| Delayed Diagnosis | 1 | 2018 | 1529 | 0.36 | Why? |
| Endothelial Progenitor Cells | 2 | 2020 | 103 | 0.35 | Why? |
| Dyspnea | 2 | 2018 | 3847 | 0.32 | Why? |
| von Willebrand Factor | 3 | 2021 | 668 | 0.32 | Why? |
| Hemoptysis | 2 | 2019 | 172 | 0.31 | Why? |
| Pregnancy Complications, Cardiovascular | 2 | 2019 | 231 | 0.30 | Why? |
| Venous Thromboembolism | 5 | 2021 | 4273 | 0.23 | Why? |
| Fibrin Fibrinogen Degradation Products | 8 | 2021 | 5993 | 0.23 | Why? |
| Endothelium, Vascular | 4 | 2021 | 1751 | 0.22 | Why? |
| Heart, Artificial | 1 | 2020 | 35 | 0.22 | Why? |
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 66 | 0.21 | Why? |
| Myelopoiesis | 1 | 2021 | 116 | 0.21 | Why? |
| Antigens, CD19 | 1 | 2020 | 98 | 0.21 | Why? |
| Vascular Endothelial Growth Factor A | 2 | 2021 | 604 | 0.20 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 5002 | 0.20 | Why? |
| Recurrence | 3 | 2018 | 3675 | 0.20 | Why? |
| Angiopoietin-2 | 1 | 2020 | 125 | 0.19 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2021 | 262 | 0.19 | Why? |
| Embolectomy | 1 | 2018 | 101 | 0.18 | Why? |
| France | 6 | 2021 | 12074 | 0.18 | Why? |
| Endoglin | 1 | 2017 | 16 | 0.18 | Why? |
| Dilatation, Pathologic | 1 | 2017 | 78 | 0.18 | Why? |
| Chest Pain | 2 | 2020 | 578 | 0.17 | Why? |
| Neovascularization, Pathologic | 1 | 2021 | 305 | 0.17 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.17 | Why? |
| Venous Thrombosis | 4 | 2021 | 2739 | 0.17 | Why? |
| Computed Tomography Angiography | 4 | 2020 | 2153 | 0.16 | Why? |
| Prospective Studies | 11 | 2021 | 43301 | 0.16 | Why? |
| Neovascularization, Physiologic | 1 | 2017 | 160 | 0.16 | Why? |
| Anticoagulants | 7 | 2021 | 9563 | 0.15 | Why? |
| Prognosis | 7 | 2021 | 32490 | 0.14 | Why? |
| Pulmonary Artery | 2 | 2018 | 803 | 0.14 | Why? |
| Multidetector Computed Tomography | 1 | 2017 | 307 | 0.14 | Why? |
| Arterial Occlusive Diseases | 1 | 2018 | 363 | 0.13 | Why? |
| Fibrinogen | 1 | 2018 | 1048 | 0.12 | Why? |
| ROC Curve | 3 | 2021 | 6024 | 0.12 | Why? |
| Paris | 3 | 2021 | 1287 | 0.11 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2020 | 1731 | 0.11 | Why? |
| Belgium | 1 | 2017 | 2064 | 0.11 | Why? |
| Hospital Mortality | 8 | 2021 | 22087 | 0.11 | Why? |
| Tissue Plasminogen Activator | 1 | 2017 | 778 | 0.11 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.10 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.10 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.10 | Why? |
| Echocardiography | 3 | 2019 | 3661 | 0.10 | Why? |
| Switzerland | 1 | 2017 | 2738 | 0.10 | Why? |
| Respiratory Tract Diseases | 1 | 2018 | 1061 | 0.10 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.10 | Why? |
| Ischemia | 1 | 2017 | 901 | 0.10 | Why? |
| Aged | 18 | 2021 | 215776 | 0.09 | Why? |
| Lung | 2 | 2018 | 31049 | 0.09 | Why? |
| Female | 21 | 2021 | 380317 | 0.09 | Why? |
| Male | 20 | 2021 | 367725 | 0.09 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.09 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.09 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.09 | Why? |
| Proportional Hazards Models | 4 | 2021 | 6543 | 0.08 | Why? |
| Kaplan-Meier Estimate | 3 | 2021 | 4260 | 0.08 | Why? |
| Biomarkers | 5 | 2021 | 23361 | 0.08 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.08 | Why? |
| Mesenchymal Stem Cell Transplantation | 1 | 2017 | 1322 | 0.07 | Why? |
| Fibrinolytic Agents | 1 | 2017 | 1702 | 0.07 | Why? |
| Intensive Care Units | 3 | 2021 | 29594 | 0.07 | Why? |
| Thrombolytic Therapy | 1 | 2017 | 2218 | 0.07 | Why? |
| Humans | 29 | 2021 | 930598 | 0.07 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.06 | Why? |
| Fibroblast Growth Factor 2 | 1 | 2021 | 77 | 0.06 | Why? |
| Adult | 11 | 2021 | 244371 | 0.06 | Why? |
| Placenta Growth Factor | 1 | 2021 | 93 | 0.05 | Why? |
| E-Selectin | 1 | 2020 | 55 | 0.05 | Why? |
| Severity of Illness Index | 5 | 2021 | 48226 | 0.05 | Why? |
| Molecular Weight | 1 | 2021 | 249 | 0.05 | Why? |
| Registries | 1 | 2020 | 12327 | 0.05 | Why? |
| Endothelial Cells | 2 | 2021 | 2048 | 0.05 | Why? |
| Collagen | 1 | 2021 | 222 | 0.05 | Why? |
| Tomography, X-Ray Computed | 4 | 2020 | 25144 | 0.05 | Why? |
| Patient Admission | 3 | 2021 | 5250 | 0.05 | Why? |
| Tachycardia | 1 | 2020 | 239 | 0.05 | Why? |
| Natriuretic Peptides | 1 | 2019 | 66 | 0.05 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.05 | Why? |
| Retrospective Studies | 6 | 2021 | 105322 | 0.05 | Why? |
| Decision Support Techniques | 1 | 2006 | 903 | 0.04 | Why? |
| Hindlimb | 1 | 2017 | 21 | 0.04 | Why? |
| Adipogenesis | 1 | 2017 | 38 | 0.04 | Why? |
| Chondrogenesis | 1 | 2017 | 19 | 0.04 | Why? |
| Vascular Remodeling | 1 | 2018 | 99 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Probability | 1 | 2021 | 923 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.04 | Why? |
| Perfusion | 1 | 2018 | 254 | 0.04 | Why? |
| Cell Adhesion | 1 | 2017 | 230 | 0.04 | Why? |
| Regional Blood Flow | 1 | 2017 | 172 | 0.04 | Why? |
| Mice, Nude | 1 | 2017 | 340 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.04 | Why? |
| Angiography | 1 | 2017 | 301 | 0.04 | Why? |
| Patients' Rooms | 1 | 2021 | 675 | 0.04 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.04 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2016 | 22971 | 0.04 | Why? |
| Protein Multimerization | 1 | 2021 | 1336 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.03 | Why? |
| Necrosis | 1 | 2017 | 532 | 0.03 | Why? |
| Transfection | 1 | 2017 | 864 | 0.03 | Why? |
| RNA Interference | 1 | 2017 | 534 | 0.03 | Why? |
| Contrast Media | 1 | 2020 | 1011 | 0.03 | Why? |
| Hemostasis | 1 | 2020 | 811 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.03 | Why? |
| Lower Extremity | 1 | 2018 | 593 | 0.03 | Why? |
| Antibodies, Antiphospholipid | 1 | 2018 | 519 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Troponin | 1 | 2019 | 1058 | 0.03 | Why? |
| Ultrasonography | 2 | 2018 | 4409 | 0.03 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| False Negative Reactions | 1 | 2017 | 1785 | 0.03 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.02 | Why? |
| Proteomics | 1 | 2020 | 2481 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.02 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.02 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.02 | Why? |
| Hemorrhage | 1 | 2020 | 3013 | 0.02 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.02 | Why? |
| Treatment Outcome | 3 | 2020 | 51732 | 0.02 | Why? |
| Emergency Service, Hospital | 2 | 2017 | 14232 | 0.02 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.02 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Drug Design | 1 | 2018 | 2627 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.01 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2006 | 9537 | 0.01 | Why? |
| Europe | 1 | 2006 | 12702 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.00 | Why? |
Sanchez's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(166)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(205)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_